Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results

Autor:	Shmalts А.А., Gorbachevsky S.V.
Jazyk:	ruština
Rok vydání:	2018
Předmět:	pulmonary arterial hypertension PAH-specific therapy soluble guanylate cyclase stimulators phosphodiesterase-5 inhibitors nitrogen oxide Diseases of the circulatory (Cardiovascular) system RC666-701
Zdroj:	Системные гипертензии, Vol 15, Iss 2, Pp 72-76 (2018)
Druh dokumentu:	article
ISSN:	2075-082X 2542-2189
DOI:	10.26442/2075-082X_15.2.72-76
Popis:	Endogen nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) deficiency in pulmonary vessels walls plays essential role in pulmonary arterial hypertension (PAH) pathogenesis. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase-5 (PDE5) inhibitor sildenafil increase cGMP content and have proven clinical efficacy in PAH treatment. The potentially beneficial mechanisms of riociguat mechanism of action include endogen NO independence in cGMP synthesis and its independence from other phosphodiesterase isoferments (other than PDE5). Clinical options, safety and effectiveness of iPDE5 – riociguat transition in patients with PAH were for the first time shown in non-controlled study RESPITE and the assessment is continued in randomized placebo-controlled trial REPLACE.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/e05252e4aeb34859ad0f3c2804e4301f Zobrazit plný text záznamu View record in DOAJ